로딩 중…
StockDiggingStockDigging

Amphastar Pharmaceuticals, Inc.

AMPH· NASDAQ
$23.85-0.42%
2026-09-17

Financials

Valuation Metrics

Amphastar Pharmaceuticals, Inc.'s Market Cap is $1.01B. At end of 2025 it was $1.23B. Ranked #2462 of 3,121 in US market (top 79%), #1010 of 1,463 on NASDAQ (top 69%), #188 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 71%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$1.01B
Revenue$730M
Net Income$79M
Total Assets$1.74B
Net Assets$768M
Employees1,976
Value
P/E12.92x
P/B1.32x
P/S1.39x
EV/EBITDA8.46x
FCF Yield15.07%
Profitability
ROE10.23%
ROA4.50%
Op. Margin15.66%
Revenue Growth1.35%
Earnings Growth-41.69%
Financial Health
Debt Ratio127.01%
Total Debt$688M
FCF$153M
Cash$224M
Current Ratio2.40x
Net Debt/EBITDA2.66x
Dividend
Div. Yield0.00%
Payout Ratio0.00%
Performance
1Y Return-11.60%
1M Return11.76%
From 52W High-23.70%
1Y MDD-45.24%
Trading
Volume350,539 shares
Trading Value$8M
Per Share
EPS$1.85
BPS$18.06

Company Info

CEO Dr. Yongfeng Zhang Ph.D.
Employees 1,976
HQ Rancho Cucamonga, United States

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.